Four-Week Neoadjuvant Intensity-Modulated Radiation Therapy With Concurrent Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer Patients: A Validation Phase II Trial - Arbea, Leire; Martínez-Monge, Rafael; Díaz-González, Juan A.; Moreno, Marta; Rodríguez, Javier; Hernández, Jose Luis; Sola, Jesús Javier; Ramos, Luis Isaac; Subtil, Jose Carlos; Nuñez, Jorge; Chopitea, Ana; Cambeiro, Mauricio; et al. (International journal of radiation oncology, biology, physics, 2012)
Keywords: Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Capecitabine; Chemoradiotherapy - adverse effects; Chemoradiotherapy - methods; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; DIARRHEA; Diarrhea - etiology; Dose Fractionation; Drug Administration Schedule; Female; Fluorouracil - administration & dosage; Fluorouracil - analogs & derivatives; Gastroenterology. Liver. Pancreas. Abdomen; Hematology, Oncology and Palliative Medicine; Humans; Intensity-modulated radiation therapy; Locally advanced rectal cancer; Male; Medical sciences; Middle Aged; Neoadjuvant Therapy - adverse effects; Neoadjuvant Therapy - methods; Neoplasm Staging; NEOPLASMS; Organoplatinum Compounds - administration & dosage; Oxaliplatin; Pathological response; Patient Compliance; PATIENTS; POLYMERASE CHAIN REACTION; Preoperative Care - methods; PROCTITIS; Proctitis - etiology; Proctitis - pathology; RADIATION DOSES; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; RADIOTHERAPY; Radiotherapy, Intensity-Modulated - adverse effects; Radiotherapy, Intensity-Modulated - methods; Rectal Neoplasms - mortality; Rectal Neoplasms - pathology; Rectal Neoplasms - therapy; RECTUM; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; SURGERY; TOXICITY; Treatment Outcome; Tumors; VALIDATION; Intensity-modulated radiation therapy; Pathological response; Locally advanced rectal cancer; Oxaliplatin; Capecitabine; Antineoplastic agent; Rectal disease; Concurrent; Neoadjuvant treatment; Cancerology; Phase II trial; Intestinal disease; Pyrimidine nucleoside; Anorectal disease; Platinum II Complexes; Human; Validation; Fluoropyrimidine derivatives; Malignant tumor; Rectum cancer; Prodrug; Alkylating agent; Intensity modulated radiotherapy; Digestive diseases; Locally advanced stage; Cancer